Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 566 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vaginal Diseases Clear all

Conditions: Endometrial Cancer
Interventions: Pembrolizumab, Vaginal cuff brachytherapy (VCB), Paclitaxel, Carboplatin; Drug · Radiation
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: New Orleans, Louisiana • Oklahoma City, Oklahoma

Conditions: Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)
Interventions: Artesunate Suppositories; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Towson, Maryland

Conditions: Overactive Bladder
Interventions: Toviaz, Premarin, Placebo cream; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 30 Years to 100 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Breast Cancer
Interventions: Questionnaires, Education Materials, Luvena, Hyalo-Gyn, Vaginal Lubricant, Interactive Internet-Based Website, Telephone Counseling.; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Vulvodynia
Interventions: Lidocaine/Diphenhydramine, lidocaine, placebo; Drug
Lead sponsor: Lumara Health, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 41
States / cities: Montgomery, Alabama • Chandler, Arizona • Phoenix, Arizona + 36 more

Conditions: Prolapse, Vaginal, Stress Urinary Incontinence, Pessaries, Pain
Interventions: Perineal massage; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Post-operative Dyspareunia
Interventions: Dilator use; Behavioral
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Perineal Injury, Pain Vulva, Perineum; Injury
Interventions: Perineal ice packs, medicated witch-hazel pads, and topical benzocaine spray; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pain Management
Interventions: Local anaesthetic, Pudendal Nerve Block plus anesthesia; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe, Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe
Interventions: clindamycin phosphate vaginal cream 2%, placebo; Drug · Other
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 15
States / cities: Birmingham, Alabama • La Mesa, California • San Diego, California + 12 more

Conditions: Recurrent Urinary Tract Infections in Women
Interventions: Immunization with inactivated bacteria; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: HIV Infections
Interventions: UC-781 microbicide gel (0.1% and 0.25%), placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Gynecologic Cancer
Interventions: prasterone, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 280
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more

Conditions: Bone; Disorder, Development and Growth
Interventions: Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring; Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Endometrial Carcinoma, Cervix Cancer, Carcinoma of the Uterus
Interventions: Radiation therapy; Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pelvic Organ Prolapse (POP)
Interventions: SSLF, ULS, PMT; Procedure · Behavioral
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 9
States / cities: Birmingham, Alabama • Bellflower, California • La Jolla, California + 6 more

Conditions: Preterm Birth
Interventions: Clamp cord 20, 40 or 60 seconds following vaginal or cesarean delivery; Other
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Recurrent Urinary Tract Infection
Interventions: Estradiol vaginal cream, Estradiol Vaginal Tablet; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 20 Years to 80 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Sexual Dysfunction, Physiological
Interventions: Vaginal Renewal Program, Vaginal Dilator; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Vaginal Cancer, Vulvar Cancer
Interventions: topotecan hydrochloride, pharmacological study; Drug · Other
Lead sponsor: Steven Waggoner, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
Interventions: Ibrexafungerp; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Rogers, Arkansas

Conditions: Microbial Colonization
Interventions: No intervention; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 13 Years to 24 Years · Female only
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pain Management, Vaginal Delivery
Interventions: Abdominal binder; Device
Lead sponsor: Wright State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Dayton, Ohio

Search by objective public record fields.

Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

Premarin Versus Toviaz for Treatment of Overactive Bladder

Preventing Sexual Dysfunction With Aromatase Inhibitors

Safety and Efficacy of Two Vaginal Products Versus Placebo in Patients With Vaginal Discomfort

Perineal Massage for Pessary Examinations

Dilators for Dyspareunia Prevention

Improving Postoperative Recovery: A Study of Multimodal Perineal Analgesia Protocol (MPAP) After Vaginal Surgery

Pudendal Enhancement of Enhanced Recovery After Surgery (ERAS) for Reconstructive Surgery (PEERS)

Vaccine for Recurrent Urinary Tract Infections in Women

Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma

Operations and Pelvic Muscle Training in the Management of Apical Support Loss: The OPTIMAL Trial

Optimal Timing of Cord Clamping in Preterm Pregnancy Following Vaginal or Cesarean Delivery

Preference of Women With Recurrent Urinary Tract Infection for Vaginal Estradiol Tablet vs Cream

Evaluation of The Vaginal Renewal™ Program in Gynecologic Cancer Patients Experiencing Sexual Dysfunction

A Study to Monitor Patients With Primary or Early HIV Infection

Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery

Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp

Vaginal Microbiota, and STI/HIV Risk Among Adolescent Girls and Young Women

Post-partum Non-pharmacologic Pain Management